Europe’s expert medicines panel has rejected Puma Biotechnology’s breast cancer drug neratinib, citing limitations in its efficacy and safety concerns. The rejection of neratinib on Friday by the European Medicines Agency’s CHMP didn’t come as a s...
Original Article: EU cancer drugs rejection shows contrasts with FDA